Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Next Level
All O'''board...
.60...
.70...
Then the 1.00$$$
TK
Talk about resistance! Four days at .58 high.
>DEW, what do u think is happening with all this price action?<
GENR has become a trading vehicle. The recent price movements may have little or nothing to do with the business.
>where do u see genr going from here?<
I think the company itself is doomed unless there is a bona fide breakthrough with the IL9 program. Regarding the share price, your guess is as good as mine. However, I cannot see the price getting back to $1 without hard, non-BS news. Regards, Dew
>…I would assume if it hits phase 3 and the Dept of Defense funds that, some time near future, and DNDN get a final letter of approval from the FDA, this stock could be the next 20 buck stock…. Opinions?<
Ludicrous, IMO.
Squalamine is being tested in prostate cancer on a shoestring government grant at a single clinical site. The enrollment in this trial is so slow that the trial may not be completed in our lifetimes.
Bottom line is that Squalamine is not a serious cancer drug.
Ok heres my question/head scratcher. What about Squalamine lactate? Could this be a part of the sale of the (non core assets) that they mentioned. Could it be the reason this stock is showing more action, because of the possability of the FDA approval to DNDN for there prostate cancer drug? There was no mention of Squalamine in there PR. Squalamine is in Phase 2 and is being funded by the Dept of Defense so I would assume if it hits phase 3 and the Dept of Defense funds that, some time near future, and DNDN get a final letter of approval from the FDA, this stock could be the next 20 buck stock. They would have hardley no out of pocket expenses on Squalamine and have roughly 40 mil to get thru the end of 2008 w/ no debt. Opinions?
Hi Tina, nice to see you posting at GENR again !
They are putting the right pieces together, finally!
I think they can get this over 1, before their time frame is up.
IMO
Three Kings
FOR IMMEDIATE RELEASE
Contact:
Genaera Corporation
Sam Brown Inc. (Media Inquiries)
Investor Relations
Mike Beyer
(610) 941-5675
(773) 463-4211
www.genaera.com
beyer@sambrown.com
GENAERA CORPORATION COMPLETES STRATEGIC REVIEW AND ANNOUNCES PLAN TO FOCUS RESOURCES ON OBESITY AND ASTHMA PROGRAMS
Plymouth Meeting, PA – April 10, 2007 – Genaera Corporation (NASDAQ: GENR) today announced that its Board of Directors has approved management’s plan to focus corporate resources on the development of trodusquemine (MSI-1436) for the treatment of obesity. Trodusquemine development, along with Genaera’s partnership with MedImmune, Inc. on the development of anti-interleukin-9 (IL9) antibody for the treatment of asthma, will form the cornerstone of Genaera’s research activities over the next year. In connection with this realignment, Genaera will reduce its workforce by approximately 30 percent over the next three months and pursue the divestiture of certain non-core assets.
“We have conducted an exhaustive review of our strategic alternatives in the wake of the termination of the EVIZON wet AMD program in January, and we have determined that our best opportunities for success moving forward are to concentrate our internal efforts on progressing trodusquemine efficiently into the clinic, while MedImmune continues to advance development of our anti-IL9 antibody,” said Jack Armstrong, President and Chief Executive Officer of Genaera. “We believe that this research focus and our strong cash position will allow us to capitalize on the clinical promise and market potential of these exciting programs and deliver the inherent value of the science and technology underlying the Genaera research pipeline.”
Trodusquemine (MSI-1436) is a centrally-acting appetite-suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme target for the treatment of diabetes and obesity. MSI-1436 produces consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, MSI-1436 has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation. Genaera expects to initiate a phase 1 clinical study of trodusquemine by the end of the second quarter of 2007.
The anti-IL9 antibody, MEDI-528, is currently in phase 2 for the treatment of asthma. IL9 has been implicated in the pathogenesis of asthma and other respiratory diseases. Data from studies in preclinical models of asthma suggest that IL9 neutralizing monoclonal antibodies may help reduce airway hyper-reactivity, mucous production and inflammation. Anti-IL9 technology, based on Genaera research, has been licensed to MedImmune, Inc. to develop and
commercialize. Genaera could receive up to $54.0 million in future milestone payments and is entitled to royalties on sales of commercial products resulting from the collaboration.
The Company estimates that it will incur restructuring charges of approximately $0.5 million in the second and third quarters of 2007 associated with the reduction in force. As of December 31, 2006, Genaera had cash and cash equivalents of approximately $33.8 million. The Company believes that cash on hand is sufficient to fund operations through 2008.
About Genaera
Genaera Corporation is a biopharmaceutical company focused on the development of innovative drug candidates in the areas of obesity, metabolic diseases and asthma. The Company is focusing on the development of trodusquemine (MSI-1436) as a treatment for obesity and the continuation of the anti-IL9 antibody program for the treatment of asthma. Genaera’s other compounds include LOMUCIN™, a mucoregulator to treat the overproduction of mucus and secretions involved in many forms of chronic respiratory disease; squalamine for the treatment of cancer; and LOCILEX™ (pexiganan acetate), a topical antimicrobial.
This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “believe,” “continue,” “develop,” “expect,” “plan” and “potential” or other words of similar meaning. Genaera’s actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera’s history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera’s product candidates may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera’s reliance on its collaborators, in connection with the development and commercialization of Genaera’s product candidates; market acceptance of Genaera’s products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera’s filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.
Dew is a "GENR" expert so please do not attack posters that ask him GENR related questions (which are on topic).
Thanks
Three Kings, not to leave anyone out, just curious what dew thought, what do u think as well is going to play out here? and what is moving this stock all of a sudden after it has been dead for so long?
all the best
chance of sale of co. soon? they have cutback so much staff at this point is all that is left to finally sell the co.?
management has really disappointed shareholders.
We make money here...
For dewy boy???
http://www.investorshub.com/boards/board.asp?board_id=1418
Three Kings
DEW, what do u think is happening with all this price action?
where do u see genr going from here?
Look for the 2nd white candle
Buy with both hands, if it happens...
Finally got the t#rds out of there that fumbled so many times.Somebody is buying in hard now. Medimune news may be reason right now. Go look at yahoo boards and read some of the good discusions after weeding out the caca. My dry eyes are hurting.
It will see 1
I told that to a friend...
He owes me...
Three Kings
GENR up 11.79 % today, continuing on its merry solid path, and only $ 0.43 away from that dollar in the sky............hello $ 1.00, I can see you now !
Back to 1... News
Genaera Corporation Names New Chief Financial Officer
Genaera Corporation Completes Strategic Review and Announces Plan to Focus Resources on Obesity and Asthma Programs
Three Kings
Dew .....
Beg to differ with you on that. You can stay with GENR at 50 cents, I'm moving on with it to $1.00 with or without the IL-9 program. Don't forget.....there is nothing rational about the human species. You're trying to be logical.
>…if the company manages to get the PPS back over a dollar per share to satisfy the Nasdaq Listing Requirement by the deadline…<
That won’t happen unless there is some bona fide progress with respect to the IL-9 program.
There are so many shares outstanding that $1 is not a cheap valuation.
Ultimately in the whole scheme of things.....if the company manages to get the PPS back over a dollar per share to satisfy the Nasdaq Listing Requirement by the deadline, having reduced the Lomucin trial by 60 % doesn't mean much .
One White...(candle)
Looking for 2...
Then buy with both hands...
lol
Three Kings
Stock is valued at the cash on hand price now---need some good news to get it back over the 1.00 range. Someone help their PR department pleeeeease.
The Lomucin trial has been reduced by 60% (from 200 patients to 80):
http://www.sec.gov/Archives/edgar/data/880431/000119312507072115/d8k.htm
It would probably make more sense to end the trial now—and thereby conserve as much cash as possible—because the whole Lomucin program is a freaking joke, IMO.
When she fills the last gap...
She will return to 1...
Three Kings
WOW! and skimming under the Radar!
The RSI on the charts are in the BoooYaa! Zone
The charts look Great!
What a turnaround!!
I can't believe you mod this board... I held Generea most of the year last year, I even found the headquarters and drove around there parking lot... There headquarters are near my home..
$ 0.499 close with 328,213 shares traded and an intraday high of $ 0.51.........we're half way there to my silly $ 1.00 per share. Come on next week !
XMARK Opportunity Partners disclosed 9.7% stake in GENR.
From their filed SC-13D :
" The Funds acquired common shares of the Company or the right to acquire common shares of the Company reported on this SC-13D because Opportunity Partners believes that the common shares are undervalued and represent an attractive investment opportunity. Opportunity Partners intends to pursue discussions with the Company's Management and Board of Directors with respect to the Company's current direction.....etc.etc.etc. "
Opportunity Partners apparently believes that the Company ( GENR ) should focus on MSI -1436 product candidate which in their opinion has great promise as an anti-obesity compound.
Considering the number of upsized Big-Macs and upsized fries we have consumed in this country over the last few decades, OP might have a point of contention.....just my silly opinion folks. Could be one heck of a market.
Somethings brewing up there. Think we will see some big changes in the guard. Get er done.
What do Lloyd Miller and Xmark Partners know that we average investors dont, they are both betting Big money here, getting interesting again, hope we have new management soon.
Some gave up I suppose, some moved to Investor Village Board, and there is some activity over at the Yahoo board.
Our moderator is a lot prettier though with a good sense of humor. Besides that the news release today by a party that owns over 9% of the stock planning on giving the Board of Directors some advice doesn't seem to be hurting either.
Getting a four bagger in a few months may not represent world class returns but I'll take it by June and we'll see where we go from there.
Enjoy the peace and quiet over here Yafu. Thanks for speaking up.
Amazing this board isn't more populated!
GENR is a double since the first of the year!!
I was crowing back in 2003 when I bought it @ .33 and sold it
for a double back then. gheeze! A double! Gheeze!!!!!!!!!
Like then, in with too few. Shudda refied the house!
double dmnn^&$%*&@%%*^#!@(#&!@(!@)%!
Well....as soon as I finished that post, it jumped to $ 0.52 ,
come on breakout ! Hello $ 1.00 ....I can see you now !
Tend to agree with you. Steady clawing motion upward with decent volume over the last few weeks. Looks as if we are crawling toward a close of $ 0.50 today. Steady as she goes !
Need some good news--seems to me this move is in relation to the cash on hand and where the value needs to be without some good news. Have been in and out of this stock for years. I need it to get back to 1.00 so get that pipeline moving again.
GENR averaged just shy of about 4% per day for the last six trading days for a total gain of about 23% since the opening bell on 3/12/07......talking to myself just really seems to work. Good volume too......imagine that, even on a slow day at the Casino.
Dew.....have you changed your mind yet ? Think we're going for that Dollar in the Sky !
Re: DEW - you always need a Contrarian.
Usually I don't have much time to post. Have 94 positions in 7 portfolios ( my own ) which tend to keep me occupied. Always appreciate contrarian viewpoints also. " The downtrodden Penny Dragons " can actually be a lot of fun and fill a lot of Leprechaun's gold pots. I'll take the Luck o' the Irish over any " Wall Street's ANALyst's viewpoint any day though. The Street didn't do so good the past few weeks ......didn't seem to affect the leprechaun's activities. Just another blasted Pot O' Gold.
LOL thanks HAK sweetie!
Be careful! dew is anti GENR!
Thanks !
Delighted to see you are still on this board and haven't been abducted by serious Alien Investors.
Message to DewDiligence : I reeeeeally like Tina Marie !
Happy St. Patrick's Day Lassie ! Love your Avatar signature.
I like GENR even if it only makes it to $ 1.10, but, somehow I have a feeling, the Amateurs are going to delight me in the next few months.
that's definitely not a silly investor!
Good luck to ya :)
Upward pps pressure appears to continue, all the serious investors may be gone but it certainly appears that the amateurs are trying to drive this above the $ 1.00 marker by June to satisfy Nasdaq relisting. Since I picked up the shares in the 0.20's ....if I get get a four bagger in three months, you can call me a silly investor all day long !
Talking to myself seems to really work !
Thanks DEW ....appreciate your response.
>Where did you all go ? ..... to an intergalactic party ?.....were all of you abducted?<
Serious investors are long gone because all the company has left is a piece of MEDI’s IL-9 program, which has not exactly been on the fast track.
GENR's nice move upward today ( 15.38 % ) with 2,125,106 shares traded and this board is deader than a door nail.
Where did you all go ? ..... to an intergalactic party ?.....were all of you abducted ?
Good Grief.....I'll be conversing with myself here pretty soon.
Sorry, I don’t know anything about XKEM.
p.s. Thanks, Tina, for being a good traffic cop
you have to reply to one of his posts
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
234
|
Created
|
07/17/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |